Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) have received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Brokers have set a 12-month consensus target price of $4.50 for the company, according to Zacks. Zacks has also given ContraVir Pharmaceuticals an industry rank of 158 out of 265 based on the ratings given to related companies.
Separately, Maxim Group set a $4.00 price objective on ContraVir Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, October 19th.
Shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) opened at $0.33 on Friday. The company has a market capitalization of $25.84, a price-to-earnings ratio of -1.38 and a beta of 1.43. ContraVir Pharmaceuticals has a 1 year low of $0.32 and a 1 year high of $1.96.
TRADEMARK VIOLATION WARNING: This piece was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3128041/contravir-pharmaceuticals-inc-ctrv-given-consensus-recommendation-of-strong-buy-by-analysts.html.
About ContraVir Pharmaceuticals
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.